Fractyl Health appoints Michael Wartell as independent director
GUTS•Fractyl Health appointed Michael Wartell as an independent Class III director effective November 2, 2026, expanding its board from nine to 10 members.
GUTS•GUTS•GUTS•Fractyl Health appointed Michael Wartell as an independent Class III director effective November 2, 2026, expanding its board from nine to 10 members.
Wartell’s term expires at the 2027 annual shareholder meeting. He is president of Bluerose Associates and has more than 35 years of investment experience and extensive public- and private-company board experience.
